Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

1.

The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.

Yenice N, Mehtap O, Gümrah M, Arican N.

Turk J Gastroenterol. 2006 Jun;17(2):94-8.

PMID:
16830289
[PubMed - indexed for MEDLINE]
2.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

PMID:
15461877
[PubMed - indexed for MEDLINE]
Free Article
3.

Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.

Baker DE.

Rev Gastroenterol Disord. 2003 Spring;3(2):93-109. Review.

PMID:
12776006
[PubMed - indexed for MEDLINE]
4.

Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response.

Zeuzem S, Poordad F.

Curr Med Res Opin. 2010 Jul;26(7):1733-43. doi: 10.1185/03007995.2010.487038. Review.

PMID:
20482242
[PubMed - indexed for MEDLINE]
5.

Role of ribavirin in HCV treatment response: now and in the future.

Jain MK, Zoellner C.

Expert Opin Pharmacother. 2010 Mar;11(4):673-83. doi: 10.1517/14656560903580001. Review.

PMID:
20163278
[PubMed - indexed for MEDLINE]
6.

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.

Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P.

Liver Int. 2010 Oct;30(9):1259-69. doi: 10.1111/j.1478-3231.2010.02283.x. Review.

PMID:
20633102
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

[Attempts to treat chronic hepatitis C with HCV protease inhibitor].

Pawłowska M.

Przegl Epidemiol. 2011;65(1):35-8. Review. Polish.

PMID:
21735833
[PubMed - indexed for MEDLINE]
8.

Peginterferon and ribavirin for chronic hepatitis C.

Hoofnagle JH, Seeff LB.

N Engl J Med. 2006 Dec 7;355(23):2444-51. Review. No abstract available.

PMID:
17151366
[PubMed - indexed for MEDLINE]
9.

Treatment of chronic hepatitis C.

Bihl F, Negro F.

Minerva Med. 2009 Dec;100(6):459-65. Review.

PMID:
20010481
[PubMed - indexed for MEDLINE]
10.

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.

Pawlotsky JM.

Hepatology. 2011 May;53(5):1742-51. doi: 10.1002/hep.24262. Review.

PMID:
21374691
[PubMed - indexed for MEDLINE]
11.

Modeling hepatitis C virus therapies combining drugs and lectin affinity plasmapheresis.

Tullis RH, Duffin RP, Ichim TE, Joyce JA, Levin NW.

Blood Purif. 2010;29(2):210-5. doi: 10.1159/000245649. Epub 2010 Jan 8. Review.

PMID:
20093829
[PubMed - indexed for MEDLINE]
12.

A review of the treatment of chronic hepatitis C virus infection in cirrhosis.

Vezali E, Aghemo A, Colombo M.

Clin Ther. 2010 Dec;32(13):2117-38. doi: 10.1016/S0149-2918(11)00022-1. Review.

PMID:
21316532
[PubMed - indexed for MEDLINE]
13.

[Antiviral therapy for chronic hepatitis C: current status and perspectives].

Takehara T.

Yakugaku Zasshi. 2010 Feb;130(2):143-56. Review. Japanese.

PMID:
20118636
[PubMed - indexed for MEDLINE]
Free Article
14.

[Adherence to pegylated combination therapy in patients with chronic hepatitis C. Importance of the hepatologist, general practitioner, and nurse].

Wartelle-Bladou C, Rosenthal E, Ratziu V, De Lédinghen V, Lang JP, Poynard T.

Gastroenterol Clin Biol. 2008 Mar;32(3 Pt 2):S96-S108. doi: 10.1016/S0399-8320(08)73272-X. Review. French.

PMID:
18675187
[PubMed - indexed for MEDLINE]
Free Article
15.

Hepatitis C pharmacogenetics: state of the art in 2010.

Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB; Pharmacogenetics and Hepatitis C Meeting Participants.

Hepatology. 2011 Jan;53(1):336-45. doi: 10.1002/hep.24052. Review.

PMID:
21254181
[PubMed - indexed for MEDLINE]
16.

Clinical practice. Chronic hepatitis C infection.

Rosen HR.

N Engl J Med. 2011 Jun 23;364(25):2429-38. doi: 10.1056/NEJMcp1006613. Review. No abstract available.

PMID:
21696309
[PubMed - indexed for MEDLINE]
17.

[New therapeutic options in chronic hepatitis C virus infection].

Hunyady B.

Orv Hetil. 2011 May 29;152(22):887-97. doi: 10.1556/OH.2011.29112. Review. Hungarian.

PMID:
21565757
[PubMed - indexed for MEDLINE]
18.

New HCV therapies on the horizon.

Vermehren J, Sarrazin C.

Clin Microbiol Infect. 2011 Feb;17(2):122-34. doi: 10.1111/j.1469-0691.2010.03430.x. Review.

PMID:
21087349
[PubMed - indexed for MEDLINE]
19.

Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.

Aghemo A, Rumi MG, Colombo M.

Nat Rev Gastroenterol Hepatol. 2010 Sep;7(9):485-94. doi: 10.1038/nrgastro.2010.101. Epub 2010 Jul 20. Review.

PMID:
20644567
[PubMed - indexed for MEDLINE]
20.

Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.

Naggie S, Patel K, McHutchison J.

J Antimicrob Chemother. 2010 Oct;65(10):2063-9. doi: 10.1093/jac/dkq284. Epub 2010 Aug 4. Review.

PMID:
20688770
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk